GlassScriptPhysician profile
Mary M Mogan
NPI 1326420324
$5,722.10
in general payments reported to CMS, 2019-2025
27 companies · $19.78 in 2025
The $19.78 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $1,339 · 2023: $2,184 · 2024: $1,188 · 2025: $19.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,166.56 | 2021-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $787.01 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $763.22 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $397.03 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.35 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $302.66 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $263.00 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $237.04 | 2022-2024 | Opsumit, Uptravi |
| Pfizer INC. | $191.51 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $164.57 | 2021-2023 | Eliquis |
| Edwards Lifesciences Corporation | $144.36 | 2022-2024 | |
| Novo Nordisk INC | $125.41 | 2023-2024 | Ozempic, Rybelsus |
| Zoll Circulation INC | $110.05 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Esperion Therapeutics, INC. | $109.21 | 2022-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $105.68 | 2021-2024 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $94.47 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $93.95 | 2023-2024 | Inpefa |
| Heartflow, INC. | $56.16 | 2022-2023 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $53.16 | 2022-2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $46.08 | 2023-2024 | |
| Scpharmaceuticals INC. | $43.40 | 2023 | |
| Alnylam Pharmaceuticals INC. | $23.67 | 2024 | Onpattro |
| Azurity Pharmaceuticals, INC. | $23.14 | 2023 | Edarbi |
| Daiichi Sankyo INC. | $20.94 | 2023 | Injectafer |
| Abbott Laboratories | $17.44 | 2021 | |
| Amarin Pharma, INC. | $16.47 | 2022 | |
| Baxter Healthcare | $14.56 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Mogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.